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Efficacy of Rosuvastatin Among Men and
Women With Moderate Chronic Kidney Disease
and Elevated High-Sensitivity C-Reactive Protein
A Secondary Analysis From the JUPITER (Justification for the Use of
Statins in Prevention–an Intervention Trial Evaluating Rosuvastatin) Trial
Paul M Ridker, MD, MPH,*† Jean MacFadyen, BS,* Michael Cressman, DO,‡ Robert J. Glynn, SCD*
Boston, Massachusetts; and Wilmington, Delaware
Objectives We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kid-
ney disease (CKD).
Background Whether patents with moderate CKD (estimated glomerular filtration rate [eGFR] 60 ml/min/1.73 m2) benefit
from statin therapy is uncertain, particularly among those without hyperlipidemia or known cardiovascular dis-
ease.
Methods Within the JUPITER (Justification for the Use of statins in Prevention–an Intervention Trial Evaluating Rosuvastatin)
primary prevention trial of rosuvastatin 20 mg compared with placebo among men and women free of cardiovascular
disease who had low-density lipoprotein cholesterol (LDL-C) 130 mg/dl and high-sensitivity C-reactive protein
(hsCRP) 2 mg/l, we performed a secondary analysis comparing cardiovascular and mortality outcomes among
those with moderate CKD at study entry (n  3,267) with those with baseline eGFR 60 ml/min/1.73 m2 (n 
14,528). Median follow-up was 1.9 years (maximum 5 years).
Results Compared with those with eGFR 60 ml/min/1.73 m2, JUPITER participants with moderate CKD had higher
vascular event rates (hazard ratio [HR]: 1.54, 95% confidence interval [CI]: 1.23 to 1.92, p  0.0002). Among
those with moderate CKD, rosuvastatin was associated with a 45% reduction in risk of myocardial infarction,
stroke, hospital stay for unstable angina, arterial revascularization, or confirmed cardiovascular death (HR: 0.55,
95% CI: 0.38 to 0.82, p  0.002) and a 44% reduction in all-cause mortality (HR: 0.56, 95% CI: 0.37 to 0.85, p
 0.005). Median LDL-C and hsCRP reductions as well as side effect profiles associated with rosuvastatin were
similar among those with and without CKD. Median eGFR at 12 months was marginally improved among those
allocated to rosuvastatin as compared with placebo.
Conclusions Rosuvastatin reduces first cardiovascular events and all-cause mortality among men and women with LDL-C
130 mg/dl, elevated hsCRP, and concomitant evidence of moderate CKD. (JUPITER—Crestor 20 mg Versus
Placebo in Prevention of Cardiovascular [CV] Events; NCT00239681) (J Am Coll Cardiol 2010;55:1266–73)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.020v
t
r
G
R
Z
B
t
i
i
r
Iompared with individuals with more preserved renal func-
ion, those with moderate chronic kidney disease (CKD)
estimated glomerular filtration rate [eGFR]60ml/min/1.73
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March 23, 2010:1266–73 Rosuvastatin, hsCRP, and Moderate CKDommunity about the relative efficacy of statin therapy among
hose with moderate CKD. This is particularly relevant in
rimary prevention where available data are scarce; in the
OSCOPS (West of Scotland Coronary Prevention Study)
rimary prevention trial, pravastatin had no significant benefit
n clinical cardiovascular events among those with CKD,
espite evidence in the same trial of efficacy among those with
GFR60 ml/min/1.73 m2 and evidence of efficacy based on
meta-analysis of secondary prevention trials conducted
mong patients with and without CKD (6).
The recently completed JUPITER (Justification for the Use
f statins in Prevention–an Intervention Trial Evaluating
osuvastatin) trial of 17,802men and women with low-density
ipoprotein cholesterol (LDL-C) 130 mg/dl but elevated
igh-sensitivity C-reactive protein (hsCRP) (2 mg/l) dem-
nstrated a 44% reduction in major vascular events and a 20%
eduction in all-cause mortality for those allocated to rosuvas-
atin 20 mg as compared with placebo during a median
ollow-up of 1.9 years (maximum 5 years) (7). Because the
UPITER trial included 3,267 primary prevention patients
ith eGFR 60 ml/min/1.73 m2 at trial entry, we had the
pportunity to perform a secondary analysis of these data
ccording to the presence or absence of moderate CKD.
ethods
he study population derived from the JUPITER trial, a
andomized, double-blind, placebo-controlled trial designed
o investigate whether rosuvastatin 20 mg daily compared
ith placebo decreases the rate of first-ever cardiovascular
vents among apparently healthy men over age 50 years and
omen over age 60 years with LDL-C 130 mg/dl at
ncreased vascular risk due to hsCRP 2 mg/l (7,8).
Full details of the trial protocol, procedures, and
ethods of confirming clinical end points and ascertain-
ng adverse events have been previously presented. Trial
xclusion criteria included treatment within 6 weeks of
creening with any lipid lowering therapies, current use of
ormone replacement therapy, evidence of hepatic dys-
unction, creatinine 2.0 mg/dl, diabetes, uncontrolled
ypertension, prior malignancy, uncontrolled hypothy-
oidism, or a recent history of alcohol, drug abuse, or
ther medical condition that might compromise safety.
ecause a core scientific hypothesis of the JUPITER trial
elated to underlying low-grade inflammation, individuals with
onditions such as severe arthritis, lupus, or inflammatory
owel disease were excluded, as were individuals taking immu-
osuppressant agents. As previously reported, allocation to
osuvastatin was associated with a 44% reduction in the trial
rimary end point (nonfatal myocardial infarction, nonfatal
troke, hospital stay for unstable angina, arterial revasculariza-
ion, or cardiovascular death) (7) as well as a 43% reduction in
he pre-specified secondary end point of incident venous
hromboembolism (8).
Study participants had baseline creatinine levels mea-ured, which were used to calculate eGFR with the rodified Diet and Renal Dis-
ase method. Baseline clinical
haracteristics of the study pop-
lation were compared between
hose with moderate CKD at
aseline and those with baseline
GFR 60 ml/min/1.73 m2; in
hese analyses, significance was
valuated with t tests for con-
inuous variables and the chi-
quare test for proportions. In
tratified analyses according to
GFR at study entry, Cox pro-
ortional hazards models were
sed to calculate hazard ratios (HRs) and 95% confidence
ntervals (CIs) for the comparison of event rates between
hose allocated to rosuvastatin or placebo. All analyses
ere performed on an intention-to-treat basis. Analyses
ere performed for the JUPITER pre-specified primary
nd point (nonfatal myocardial infarction, nonfatal
troke, hospital stay for unstable angina, arterial revascu-
arization, or confirmed cardiovascular death) and for
ombined end points that additionally included incident
enous thromboembolism and all-cause mortality. Per
rotocol, number needed to treat [NNT] values were
alculated as the reciprocal of the absolute difference
etween risks of the outcome of interest based on
aplan-Meier estimates. Estimated 95% CIs for the
NT were based on inversion of the CIs for risk
ifferences with standard errors of risks estimated by
reenwood’s formula. Consistent with prior JUPITER
ublications, 5-year NNT values were computed on the
asis of 4-year absolute rates projected over an average
-year period according to the methods of Altman and
nderson (9).
esults
aseline characteristics. Of participants in the JUPITER
rial, 3,267 (18%) had baseline eGFR 60 ml/min/1.73 m2),
hereas 14,528 (82%) had higher levels. Seven participants
id not have eGFR values available. Among those with
educed eGFR, 3,253 had stage 3 impairment (eGFR
etween 30 and 59 ml/min/1.73 m2) and 14 had stage 4
mpairment (eGFR between 15 and 29 ml/min/1.73 m2).
Study participants with moderate CKD were older,
ore likely to be female, more likely to have a family
istory of premature atherothrombosis, and less likely to
moke (Table 1). Median baseline levels of LDL-C,
igh-density lipoprotein cholesterol, triglycerides, apoli-
oprotein A, apolipoprotein B, and hsCRP were some-
hat higher among those with moderate CKD, whereas
lood pressure, glucose, and hemoglobin A1c were sim-
lar. Within each eGFR category, there was no imbalance
etween study characteristics among those allocated to
Abbreviations
and Acronyms
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
NNT  number needed to
treatosuvastatin or placebo.
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Rosuvastatin, hsCRP, and Moderate CKD March 23, 2010:1266–73vent rates associated with moderate CKD. Irrespective
f statin or placebo allocation, at trial conclusion 111 partici-
ants in the moderate CKD group suffered a primary trial end
oint (incidence rate 1.51 per 100 person-years) as compared
ith 282 participants in the group with more preserved eGFR
incidence rate 0.95 per 100 person-years). Thus, in crude
aseline Clinical Characteristics of Participants in the JUPITER TriTable 1 Baseline Clinical Characteristics of Participants in the
eGFR <60 ml/min/1.73
(n  3,267)
Age, yrs 70.0 (65.0–75.0)
Female 2129 (65.2)
Race/ethnicity
Caucasian 2,425 (74.2)/
Black 109 (3.3)
Hispanic 630 (19.3)
Other/unknown 103 (3.2)
Body mass index, kg/ m2 29.0 (25.9–32.6)
Blood pressure, mm Hg
Systolic 133 (122–144)
Diastolic 80 (72–85)
Current smoking 264 (8.1)
Family history of premature CHD* 464 (14.3)
hsCRP, mg/l 4.5 (3.0–7.6)
Total cholesterol, mg/dl 189 (173–203)
LDL-C, mg/dl 109 (96.0–120)
HDL-C, mg/dl 49 (40–60)
Triglycerides, mg/dl 130 (96–183)
Apolipoprotein A, mg/dl 164 (146–186)
Apolipoprotein B, mg/dl 111 (99–124)
Glucose, mg/dl 95 (89–103)
HbA1c, % 5.7 (5.5–6.0)
eGFR, ml/min/1.73 m2 56 (51–58)
ll values are median (IQR) or n (%). For high-sensitivity C-reactive protein (hsCRP), values are ba
Congestive heart disease (CHD) in a male first-degree relative before age 55 years or in a femal
eGFR  estimated glomerular filtration rate; HbA1c  hemoglobin A1c; HDL-C  high-density l
valuating Rosuvastatin; LDL-C  low-density lipoprotein cholesterol.
tudy Outcomes in the JUPITER Trial Among Those Allocated to RoTable 2 Study Outcomes in the JUPITER Trial Among Those All
eGFR <60 ml/min/1.73 m2
Randomized
Rosuvastatin
Randomized
Placebo
n Rate* n Rate* HR (95% C
Primary end point 40 1.08 71 1.95 0.55 (0.38–0
Myocardial infarction 8 0.21 20 0.54 0.40 (0.17–0
Stroke 10 0.27 14 0.38 0.71 (0.31–1
Arterial revascularization 19 0.51 39 1.07 0.48 (0.28–0
Myocardial infarction, stroke,
or confirmed
cardiovascular death
24 0.64 40 1.09 0.59 (0.36–0
Venous thromboembolism 6 0.16 17 0.46 0.34 (0.14–0
All-cause mortality 34 0.85 61 1.53 0.56 (0.37–0
Primary end point plus any
death
64 1.72 114 3.13 0.55 (0.41–0
Primary end point plus VTE
plus any death
69 1.86 127 3.51 0.53 (0.40–0Rates are per 100 person-years.
CI  confidence interval; HR  hazard ratio; VTE  venous thromboembolism; other abbreviations asnalysis, those with lower eGFR at study entry were at
ignificantly higher risk of developing a study primary end
oint during follow-up (HR: 1.54, 95% CI: 1.23 to 1.92, p 
.0002). Those with lower eGFR were at increased risk of
eveloping myocardial infarction, stroke, or cardiovascular
eath (HR: 1.44, 95% CI: 1.08 to 1.92, p  0.02) as well as
cording to Entry eGFRTER Trial According to Entry eGFR
eGFR >60 ml/min/1.73 m2
(n  14,528) p Value
65.0 (60.0–70.0) 0.001
4667 (32.1) 0.001
10,253 (70.6) 0.001
2,115 (14.6)
1,629 (11.2)
531 (3.7)
28.2 (25.2–31.9) 0.001
134 (124–146) 0.008
80 (75–88) 0.001
2556 (17.6) 0.001
1,581 (10.9) 0.001
4.2 (2.8–7.0) 0.001
184 (168–199) 0.001
108 (94–119) 0.001
48 (40–59) 0.03
115 (83–166) 0.001
162 (144–183) 0.001
108 (95–122) 0.001
94 (87–101) 0.001
5.7 (5.4–5.9) 0.001
77 (69–89) 0.001
the average of the screening and randomization visits. All blood values were done fasting.
egree relative before age 65 years.
ein cholesterol; JUPITER  Justification for the Use of statins in Prevention—an Intervention Trial
statin or Placebo, According to Baseline eGFRd to Rosuvastatin or Placebo, According to Baseline eGFR
eGFR >60 ml/min/1.73 m2
Randomized
Rosuvastatin
Randomized
Placebo
p Value n Rate* n Rate* HR (95% CI) p Value
0.002 102 0.69 180 1.21 0.57 (0.45–0.72) 0.001
0.02 23 0.15 48 0.32 0.48 (0.29–0.79) 0.003
0.40 23 0.15 50 0.33 0.46 (0.28–0.76) 0.002
0.006 52 0.35 92 0.62 0.57 (0.40–0.80) 0.001
0.04 59 0.40 117 0.78 0.50 (0.37–0.69) 0.001
0.02 28 0.19 43 0.29 0.65 (0.41–1.05) 0.08
0.005 164 1.04 186 1.17 0.88 (0.72–1.09) 0.25
0.0001 231 1.56 327 2.20 0.71 (0.60–0.84) 0.001
0.0001 251 1.69 356 2.41 0.70 (0.60–0.83) 0.001al AcJUPI
m2
sed on
e first-dsuvaocate
I)
.82)
.90)
.59)
.83)
.99)
.88)
.85)
.75)
.71)in Table 1.
a
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d
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March 23, 2010:1266–73 Rosuvastatin, hsCRP, and Moderate CKDrterial revascularization (HR: 1.53, 95% CI: 1.13 to 2.08, p
.008). All-cause mortality was similar in the 2 groups (inci-
ence rates 1.19 vs. 1.11 per 100 person-years, respectively;
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Figure 1 Cumulative Incidence of Cardiovascular Events in the
With and Without Moderate CKD, According to Rosuv
Panel A shows data for the JUPITER primary end point (nonfatal myocardial infarct
or cardiovascular death), whereas panel B shows data for the primary end point pR: 1.06, 95% CI: 0.85 to 1.33, p  0.61) as were rates of lenous thromboembolism (0.31 and 0.24 per 100 person-
ears, respectively; HR: 1.26, 95% CI: 0.79 to 2.02, p 0.35).
Adjustment for baseline differences between groups had
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Rosuvastatin, hsCRP, and Moderate CKD March 23, 2010:1266–73moking, and drug allocation, the HR for the primary trial
nd point comparing those with CKD with those with
reserved renal function remained 1.54 (95% CI: 1.22 to
.96, p  0.0004).
ffects of rosuvastatin on trial end points according to
aseline renal function. Among those with moderate CKD
t study entry, 71 suffered a primary trial end point among
hose allocated to placebo (incidence rate 1.95 per 100 person-
ears) as compared with 40 among those allocated to rosuvas-
atin (incidence rate 1.08 per 100 person-years, HR: 0.55, 95%
I: 0.38 to 0.82, p  0.002) (Table 2).
An almost identical effect of rosuvastatin was observed
mong those with more preserved renal function; in this
ubgroup, 180 suffered a primary trial end point among
hose allocated to placebo (incidence rate 1.21 per 100
erson-years) as compared with 102 among those allocated
o rosuvastatin (incidence rate 0.69 per 100 person-years,
R: 0.57, 95% CI: 0.45 to 0.72, p  0.001).
Figure 1A presents cumulative incidence curves for the
rimary end point among those with and without moderate
KD, according to rosuvastatin assignment. Figures 1B and
show similar data for the primary end point plus all-cause
ortality and venous thromboembolism.
As also shown in Table 2, rosuvastatin had similar
fficacy for most individual clinical outcomes within the
UPITER trial when comparing participants with and
ithout moderate CKD. A possible exception was total
ortality, which was reduced 44% by rosuvastatin among
hose with moderate CKD (HR: 0.56, 95% CI: 0.37 to
.85, p  0.005) as compared with 12% among those
0 1 2
0.
00
0.
05
0.
10
0.
15
Cu
m
ul
at
ive
 
In
ci
de
nc
e
FolloNo. at Risk
CKD      Rosuvastatin
Placebo        
No CKD Rosuvastatin
Placebo        
1,638 1,573 1,536 1,278 86
1,629 1,554 1,507 1,229 83
7,259 7,048 6,861 5,244 3,01
7,269 7,055 6,828 5,255 3,02
Primary Endpoint + VTE + AC
Figure 1 Continued
Panel C shows data for the primary end point, venous thromboembolism, and all-cith more preserved eGFR (HR: 0.88, 95% CI: 0.72 to m.09, p  0.25) (p for interaction  0.048). Effects of
osuvastatin were consistent across all pre-specified sub-
roups evaluated (Fig. 2).
Among those with moderate CKD, the NNT at 5 years
as 14 (95% CI: 9 to 30) for the primary end point and 9
95% CI: 6 to 17) for the end point that also included total
eaths and venous thromboembolism. Among those with
ore preserved renal function, the corresponding values
ere 35 (95% CI: 22 to 82) and 25 (95% CI: 16 to 58).
ffects of rosuvastatin on the change in eGFR at 12-
onth follow-up according to baseline renal function.
s previously reported (7), there is no evidence in the
UPITER trial that rosuvastatin led to any impairment of
enal function as measured by eGFR at the 12-month visit;
f anything, in the trial as a whole, median eGFR at 12
onths was marginally improved among those randomly
llocated to rosuvastatin as compared with placebo (66.8 vs.
6.6 ml/min/1.73 m2, p  0.02). In analyses stratified by
aseline eGFR, similar results were observed. Among those
ith eGFR 60 ml/min/1.73 m2 at baseline, the median
GFR levels at 12 months were 53.0 and 52.8 ml/min/1.73
2 in the rosuvastatin and placebo groups, respectively (p
.44). Among those with eGFR 60 ml/min/1.73 m2 at
aseline, the median eGFR levels at 12 months were 70.5
nd 70.0 ml/min/1.73 m2 in the rosuvastatin and placebo
roups, respectively (p  0.007).
ffects of rosuvastatin on achieved LDL-C and achieved
sCRP according to baseline renal function. Within the
UPITER trial, the largest relative risk reductions were
bserved among those who not only reduced LDL-C
3 4
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No CKD,Placebo
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March 23, 2010:1266–73 Rosuvastatin, hsCRP, and Moderate CKD0%; as reported previously, a 79% relative risk reduction
n vascular events was observed in the JUPITER trial
mong those who achieved low levels of both LDL-C
nd hsCRP (10). We thus also sought to evaluate the
eduction in both LDL-C and hsCRP according to
aseline renal function. Among those with moderate
KD, rosuvastatin reduced LDL-C by 52% and hsCRP
y 37%, whereas among those with more preserved renal
unction, LDL-C was reduced by 46% and hsCRP by
Figure 2 Effect of Rosuvastatin on the Primary Trial End Point
With and Without Moderate CKD, According to Baseli
The relative hazard ratios for the primary end point (nonfatal myocardial infarction,
firmed cardiovascular death) are shown for rosuvastatin as compared with placebo on
and on the right for those with higher eGFR values at study entry. The size of each
the horizontal lines indicate 95% confidence intervals; and the dashed vertical lin
HDL  high-density lipoprotein; hsCRP  high-sensitivity C-reactive protein; LDL-C7% (all p values 0.001) (Table 3). wafety. Adverse event rates associated with rosuvastatin
ere similar in the JUPITER trial among those with and
ithout moderate CKD (Table 4).
iscussion
n this secondary analysis of participants in the JUPITER trial,
osuvastatin was effective at reducing cardiovascular event rates
nd all-cause mortality among the 3,267 study participants
g Those
haracteristics
tal stroke, arterial revascularization, hospital stay for unstable angina, or con-
ft for those with estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2
square is proportionate to the number of participants in the subgroup;
ates the overall relative risk reduction for each group. BMI  body mass index;
density lipoprotein cholesterol.Amon
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Rosuvastatin, hsCRP, and Moderate CKD March 23, 2010:1266–73nticipated, absolute rates of future vascular disease were
igher among those with moderate CKD. Thus, absolute risk
eductions associated with rosuvastatin were higher (and NNT
alues were lower) among JUPITER participants with eGFR
60 ml/min/1.73 m2 when compared with those with higher
GFR levels. As such, these data support guidelines from the
merican Heart Association and the National Kidney Foun-
ation to provide more aggressive cardiovascular prevention
fforts among those with mild to moderately reduced renal
unction (2,3,11).
The increased absolute vascular risk in the JUPITER trial
mong those with moderate CKD is consistent with prior
ipid and hsCRP Levels During Follow-Up Among Those Allocated tTable 3 Lipid and hsCRP Levels During Follow-Up Among Those
12 Months 24
Rosuvastatin Placebo Rosuvastatin
hsCRP (mg/l)
eGFR 60 ml/min/1.73 m2 2.4 (1.4–4.7) 3.8 (2.3–6.6) 2.4 (1.4–4.8
eGFR 60 ml/min/1.73 m2 2.2 (1.2–4.4) 3.5 (1.9–6.1) 2.1 (1.2–4.1
LDL cholesterol (mg/dl)
eGFR 60 ml/min/1.73 m2 53 (42–68) 110 (95–126) 53 (43–68)
eGFR 60 ml/min/1.73 m2 57 (45–76) 106 (88–124) 55 (43–69)
HDL cholesterol (mg/dl)
eGFR 60 ml/min/1.73 m2 52 (43–64) 50 (41–61) 53 (44–65)
eGFR 60 ml/min/1.73 m2 52 (43–63) 50 (41–61) 52 (43–64)
Triglycerides (mg/dl)
eGFR 60 ml/min/1.73 m2 107 (81–143) 128 (97–182) 107 (81–141
eGFR 60 ml/min/1.73 m2 97 (72–136) 116 (85–164) 96 (71–132
ll values are median (IQR). Blood values were done fasting.
hsCRP  high-sensitivity C-reactive protein; other abbreviations as in Table 1.
ccurrence of Monitored Adverse Events, Measured Laboratoryalues, and Other Reported Events of Interest During Follow-UpTable 4 ccurrenc of Monitored Adverse Events, Measu ed LaValues, and Other Reported Events of Interest During F
eGFR <60 m
Randomized
Rosuvastatin
Ra
Monitored adverse events, n (rate)
Any serious adverse event 315 (9.16) 32
Muscular weakness, stiffness, or pain 292 (8.75) 30
Myopathy 2 (0.05)
Rhabdomyolysis 1 (0.03)*
Cancer 79 (2.10) 7
Gastrointestinal disorders 387 (12.1) 40
Renal disorders 146 (4.02) 14
Bleeding 76 (2.04) 6
Hepatic disorders 33 (0.86) 3
Laboratory values†
Creatinine, 100% increase from baseline, n (%) 3 (0.08)
ALT 3  ULN on consecutive visits, n (%) 2 (0.05)
HbA1c (% at 24 months) 5.9 (5.6–6.2) 5.
Fasting glucose (mg/dl at 24 months) 97 (90–107) 9
Other events, n (rate)
Physician reported diabetes 54 (1.44) 5
Hemorrhagic stroke 2 (0.05)ates are per 100 person-years. All blood values were done fasting. *Occurred after trial completion. †H
ALT  alanine transferase; ULN  upper limit of normal; other abbreviations as in Table 1.bservational cohorts and trials (1–3,6). However, our data
egarding the efficacy of statin therapy is consistent with
ome but not all prior data. For example, although the
ravasatatin Pooling Project found that pravastatin signifi-
antly reduced vascular event rates and mortality in a
ombined analysis of CKD patients participating in the
OSCOPS, CARE (Cholesterol and Recurrent Events),
nd LIPID (Long-term Intervention with Pravastatin in
schemic Disease) trials, the primary prevention data in this
verview were not statistically significant (6). Thus, our
nding of benefit for rosuvastatin among a primary cardio-
ascular prevention cohort who have concomitant moderate
uvastatin or Placebo, According to Baseline eGFRcated to Rosuvastatin or Placebo, According to Baseline eGFR
s 36 Months 48 Months
Placebo Rosuvastatin Placebo Rosuvastatin Placebo
.9 (2.4–6.7) 2.3 (1.2–4.3) 3.8 (2.1–6.5) 2.1 (1.2–4.0) 4.0 (2.2–6.5)
.4 (1.9–6.0) 1.9 (1.1–3.7) 3.4 (1.8–5.8) 1.8 (1.1–3.6) 3.0 (1.6–6.0)
0 (93–124) 54 (42–70) 107 (92–124) 55 (44–66) 108 (88–122)
7 (92–125) 55 (44–74) 109 (91–129) 50 (42–76) 113 (87–131)
0 (42–62) 52 (42–66) 50 (41–61) 53 (42–62) 50 (42–59)
0 (42–61) 49 (41–61) 48 (40–58) 50 (41–61) 49 (42–60)
5 (94–179) 109 (79–146) 128 (95–183) 99 (73–140) 129 (92–170)
3 (81–162) 106 (76–150) 120 (88–169) 99 (75–141) 114 (81–160)
tory
-Up
1.73 m2 eGFR >60 ml/min/1.73 m2
ized
o p Value
Randomized
Rosuvastatin
Randomized
Placebo p Value
) 0.73 1,035 (7.26) 1,056 (7.36) 0.75
) 0.52 1,129 (8.32) 1,072 (7.78) 0.15
) 0.39 8 (0.05) 5 (0.03) 0.40
— 0 (0.0) 0 (0.0) —
) 0.87 219 (1.44) 238 (1.56) 0.41
) 0.48 1,365 (10.2) 1,308 (9.64) 0.14
) 0.79 388 (2.59) 339 (2.25) 0.05
) 0.21 182 (1.20) 214 (1.41) 0.11
) 0.76 183 (1.20) 151 (0.98) 0.07
— 13 (0.08) 10 (0.06) 0.53
0.41 21 (0.14) 13 (0.08) 0.17
6.1) 0.001 5.9 (5.7–6.1) 5.8 (5.6–6.1) 0.01
106) 0.29 98 (91–106) 98 (90–107) 0.23
) 0.91 216 (1.42) 164 (1.07) 0.01
) 0.64 4 (0.03) 6 (0.04) 0.53o RosAllo
Month
) 3
) 3
11
10
5
5
) 12
) 11bora
ollow
l/min/
ndom
Placeb
0 (9.40
3 (9.24
4 (0.11
0 (0.0)
6 (2.05
3 (12.8
1 (3.90
1 (1.64
5 (0.93
0 (0.0)
4 (0.1)
8 (5.6–
6 (90–
2 (1.40
3 (0.08bA1c (%), and fasting glucose (mg/dl) are reported as median (IQR) values at 24 months.
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March 23, 2010:1266–73 Rosuvastatin, hsCRP, and Moderate CKDKD importantly extends prior data. Our observation of
enefit with rosuvastatin 20 mg in a population with
oderate CKD is also consistent with data from the
econdary prevention Treat-to-New-Targets trial where
torvastatin 80 mg was superior to atorvastatin 10 mg
mong those with and without CKD (12). By contrast, our
ata conflict with those from both the German Diabetes
nd Dialysis Study (4) and the AURORA (A Study to
valuate the Use of Rosuvastatin in Subjects on Regular
aemodialysis: an Assessment of Survival and Cardiovas-
ular Events) trial (5), where those receiving maintenance
emodialysis failed to have a clinical benefit from statin
herapy.
Patients receiving hemodialysis differ in many ways
rom those with moderate CKD, and thus our data
emonstrate that null data from these settings should not
e generalized to that of individuals without severe renal
ailure. For example, individuals receiving hemodialysis
end to have more calcification of arterial plaque than
hose with normal renal function. Nonetheless, our data
aise a potential explanation for the failure of statins in
he setting of hemodialysis; in both the German Diabetes
nd Dialysis Study and the AURORA study, LDL-C
eductions were large, but reductions in hsCRP were
mall, likely the result of chronic and repeated pro-
nflammatory stimulation associated with the dialysis
embrane (4,5). By contrast, within the JUPITER trial,
hose with and without moderate CKD had a similar magni-
ude of LDL-C and hsCRP reduction. Because both LDL-C
eduction and hsCRP reduction have been independent pre-
ictors of clinical benefit in several statin trials (13–16) as well
s in the JUPITER trial (10), the possibility that the anti-
nflammatory effects of statin therapy were blunted in the
emodialysis trials merits consideration. This hypothesis re-
uires testing in future trials.
A limitation of our analysis is that creatinine 2 mg/dl
as an exclusion criterion. Despite this exclusion, 3,276
ndividuals were randomized into the trial with eGFR 60
l/min/1.73 m2, reinforcing the observation that many
ndividuals with creatinine levels often considered in the
ormal range nonetheless have impaired renal function. Our
ndings were similar when the Cockcroft-Gault equation
as alternatively used to define eGFR. Because an entry
lucose level of 126 mg/dl was an exclusion criterion for the
UPITER trial, our study is limited to those without overt
iabetes. Finally, all JUPITER participants had elevated
sCRP, an inflammatory biomarker associated with in-
reased risk of cardiovascular events and diabetes. Therefore
t is unknown whether rosuvastatin would be effective in
rimary prevention among those with CKD and lower
sCRP levels. Keprint requests and correspondence: Dr. Paul M Ridker,
irector, Center for Cardiovascular Disease Prevention, Brigham
nd Women’s Hospital, 900 Commonwealth Avenue, Boston,
assachusetts 02215. E-mail: pridker@partners.org.
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